The Use of Infliximab in Dermatology

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 16, 3 Issues, 2017

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

The Use of Infliximab in Dermatology

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 6(3): 188-204.

Author(s): Melda Demirtasoglu and Emel Fetil.

Affiliation: Dokuz Eylul Universitesi Tip Fakultesi, Dermatoloji Anabilim Dali, Inciralti, Izmir, 35340, Turkey.


Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-α) which is major cytokine playing pivotal role in inflammatory diseases. Efficacy and safety of infliximab was studied in numerous inflammatory skin diseases where TNF-α is involved in pathogenesis especially in psoriasis and psoriatic arthritis. This review summarizes the current data revealing the efficacy and safety of infliximab in treating various dermatoses beyond its approved indications. Results of clinical trials and case reports suggest that infliximab is a promising agent in treating inflammatory cutaneous dermatoses where conventional therapies fail to respond or have limited effect due to potential side effects.


Infliximab, tumor necrosis factor-α, psoriasis, cutaneous dermatoses.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 6
Issue Number: 3
First Page: 188
Last Page: 204
Page Count: 17
DOI: 10.2174/187152307781368283
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science